http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 18 Jun 2026 09:45:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++144++++++++RECURSION+PHARMACEUTICAL+++++++++++++++Filed+by%3A+Bumpus+Namandje/26663977.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260618/AAZZ662CZ2226ZZI222K2ZZ48N6LZK2SZX82">http://archive.fast-edgar.com/20260618/AAZZ662CZ2226ZZI222K2ZZ48N6LZK2SZX82</a></p> <p> Filed on: June 18, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++144++++++++RECURSION+PHARMACEUTICAL+++++++++++++++Filed+by%3A+Bumpus+Namandje/26663977.html Thu, 18 Jun 2026 09:45:00 -0400 O.34383149 RXRX http://www.streetinsider.com/SEC+Filings/Form++144++++++++RECURSION+PHARMACEUTICAL+++++++++++++++Filed+by%3A+Bumpus+Namandje/26663977.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260618/AAZZ662CZ2226ZZI222K2ZZ48N6LZK2SZX82">http://archive.fast-edgar.com/20260618/AAZZ662CZ2226ZZI222K2ZZ48N6LZK2SZX82</a></p> <p> Filed on: June 18, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++144++++++++RECURSION+PHARMACEUTICAL+++++++++++++++Filed+by%3A+Bumpus+Namandje/26663977.html Thu, 18 Jun 2026 09:45:00 -0400 O.34383149 RXRX http://www.streetinsider.com/SEC+Filings/Form++144++++++++RECURSION+PHARMACEUTICAL+++++++++++++++Filed+by%3A+Gibson+Christopher/26663951.html si-local-file:///var/storage/secattach/20260618/26663951.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++RECURSION+PHARMACEUTICAL+++++++++++++++Filed+by%3A+Gibson+Christopher/26663951.html Thu, 18 Jun 2026 09:37:00 -0400 O.34383149 RXRX http://www.streetinsider.com/SEC+Filings/Form++144++++++++RECURSION+PHARMACEUTICAL+++++++++++++++Filed+by%3A+Gibson+Christopher/26663951.html si-local-file:///var/storage/secattach/20260618/26663951.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++RECURSION+PHARMACEUTICAL+++++++++++++++Filed+by%3A+Gibson+Christopher/26663951.html Thu, 18 Jun 2026 09:37:00 -0400 O.34383149 RXRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RECURSION+PHARMACEUTICAL++For%3A+Jun+15++Filed+by%3A+Taylor+Ben+R/26660880.html si-local-file:///var/storage/secattach/20260617/26660880.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RECURSION+PHARMACEUTICAL++For%3A+Jun+15++Filed+by%3A+Taylor+Ben+R/26660880.html Wed, 17 Jun 2026 17:07:00 -0400 O.34383149 RXRX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RECURSION+PHARMACEUTICAL++For%3A+Jun+15++Filed+by%3A+Taylor+Ben+R/26660880.html si-local-file:///var/storage/secattach/20260617/26660880.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RECURSION+PHARMACEUTICAL++For%3A+Jun+15++Filed+by%3A+Taylor+Ben+R/26660880.html Wed, 17 Jun 2026 17:07:00 -0400 O.34383149 RXRX http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR